Uniren

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uniren

Quick Facts: Uniren (Diclofenac)

Property Description
Active Ingredient Diclofenac (typically Sodium or Potassium salt)
Primary Forms Tablet, Capsule, Solution for injection, Topical gel
Pharmacological Class Non-steroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic compound
General Purpose Symptomatic relief of inflammation, pain, and fever

What Type of Medicine is Uniren?

Uniren is a synthetic pharmaceutical preparation whose active substance is Diclofenac, clinically recognized as a Non-steroidal Anti-inflammatory Drug (NSAID). This compound, a derivative of phenylacetic acid, belongs to a pharmacological class defined by its strong capacity to modulate pain and inflammation. Diclofenac is characterized as an NSAID with established anti-inflammatory, analgesic, and antipyretic actions. This confirms the medication's foundational purpose is to reduce swelling, ease discomfort, and help manage elevated body temperature.


Composition and Available Forms of Diclofenac

The composition of Uniren focuses on its active ingredient, Diclofenac, typically prepared as either the sodium or potassium salt, which influences its absorption rate in the body. As a single-ingredient product, its effects are solely derived from this compound. Diclofenac is manufactured in multiple dosage forms, facilitating diverse routes of administration tailored to the location and severity of discomfort. These forms span systemic delivery, such as oral tablets and capsules, alongside localized forms like topical gels and suppositories. The availability of localized options provides a differentiating approach for treating specific areas of discomfort, such as muscle aches.


General Purpose: Reducing Inflammation and Pain

The general purpose of Uniren is to provide comprehensive symptomatic relief by simultaneously exerting anti-inflammatory, analgesic (pain-relieving), and antipyretic effects. Diclofenac's action centers on inhibiting the production of prostaglandins, which are key chemical mediators of pain and swelling. The compound is recognized for its profile across various pain and inflammatory states. This profile ensures the medicine is functionally equipped to mitigate symptoms like swelling and tenderness that accompany acute discomfort.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

What side effects are possible with Uniren?

Possible Side Effects and Safety Information

The officially documented safety profile for Uniren outlines potential adverse reactions categorized by frequency and the body systems they affect. This information is derived from comprehensive data collected during clinical trials and post-market surveillance, adhering to authoritative government regulatory standards.

Frequency-Classified Adverse Reactions

Regulatory agencies classify adverse effects according to their likelihood of occurrence, ranging from Very Common (occurring in ge 1 in 10 patients) down to Very Rare (occurring in <1 in 10,000 patients) or Not Known (cannot be estimated from available data).

Common adverse reactions typically documented may include symptoms affecting the gastrointestinal tract, such as nausea, diarrhea, or abdominal discomfort, and those affecting the nervous system, such as headache or dizziness. These are the most frequently reported effects in regulatory texts.

System-Organ Class and Serious Reactions

Adverse effects are also systematically grouped by the System-Organ Class (SOC) affected, which includes categories like Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Hepato-biliary Disorders.

Serious adverse reactions specifically identified in regulatory documents are those considered medically significant, which may necessitate hospitalization, be life-threatening, or result in permanent disability. These serious events are highlighted to reflect their critical clinical importance.

Safety Restrictions and Considerations

The official labeling defines specific Contraindications, which are conditions where the medicine must not be used because the risk to the patient significantly outweighs the potential benefit. These may include a history of hypersensitivity to the drug's components or certain pre-existing medical conditions.

Population-specific safety cautions are documented when risks differ for certain patient groups, such as the elderly, or restrictions apply during pregnancy and lactation. Additionally, some adverse effects may be noted as dose- or duration-dependent, meaning the risk may increase with higher amounts or longer periods of use. The regulatory profile emphasizes the importance of these restrictions in defining the acceptable context for the use of Uniren.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section outlines the officially documented overdose manifestations and mandated emergency actions for Diclofenac (Uniren), as stated in regulatory documents.


Documented Overdose Manifestations

Symptoms of acute overdose primarily affect the gastrointestinal (GI) and central nervous systems (CNS). Documented manifestations commonly include nausea, vomiting, epigastric pain, headache, dizziness, and drowsiness. More severe presentations officially noted include seizures, coma, and gastrointestinal bleeding. Overdose can also lead to serious systemic complications, such as acute renal failure and hepatic toxicity.


Mandatory Emergency Action

Immediate medical attention must be sought if an overdose is suspected. Regulatory guidance states that the management of Diclofenac overdose is strictly symptomatic and supportive, as no specific antidote is known.

Procedural steps that may be utilized by healthcare professionals include the administration of activated charcoal and gastric lavage. Due to the risk of life-threatening events, hospital monitoring is required for assessing and managing complications, including severe internal hemorrhage and respiratory depression.


Population-Specific Notes

Official labeling indicates that both children and adults are at risk of severe harm from a large overdose. Additionally, an overdose taken near term during pregnancy is associated with specific fetal risks, including fetal anemia and neonatal jaundice.

Therapeutic Uses of Uniren

What Uniren Treats: Main Uses and Benefits

Uniren (Diclofenac) is used across domains where additional symptomatic support is needed, and is considered relevant in contexts involving inflammatory or irritative processes.

This medication is commonly applied in conditions characterized by periods of heightened symptoms, including chronic disorders like osteoarthritis and rheumatoid arthritis, as well as acute episodes such as sprains, strains, acute migraine attacks, and painful menstrual cramps. It helps address symptom clusters that may intensify over time, including joint pain, swelling, and stiffness.

Uniren provides supportive relief when symptoms interfere with daily functioning. The medication is often used during phases when symptoms become more noticeable to ease the overall discomfort.

“It helps address symptoms related to physical discomfort and supports patients during episodes of heightened discomfort.”

This generally contributes to easing the overall symptom load during symptomatic periods and may assist with maintaining functional stability.


Quick Fact: Relief for Inflammation, Pain, and Fever

Context Symptom Management Benefit to Patient
Chronic Conditions Joint pain, stiffness, swelling in arthritis. Contributes to easing the overall symptom load.
Acute Episodes Pain from sprains, post-surgical discomfort, migraines. Provides support that helps ease the overall symptom load.
Systemic Symptoms Elevated body temperature (fever). Supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Uniren (Diclofenac) — Official Regulatory Information

Uniren, which contains the active ingredient Diclofenac, has its eligibility profile strictly defined by regulatory documents based on contraindications and patient characteristics. Most adults and adolescents (typically over 14 years) are eligible under standard conditions, though some forms are approved for children as young as 12 months for specific indications.


Absolute Contraindications

Use is contraindicated and must not occur in patients with:

  • Known hypersensitivity to Diclofenac, aspirin, or other Non-steroidal Anti-inflammatory Drugs (NSAIDs).
  • Active gastrointestinal bleeding, ulceration, or perforation.
  • Severe heart failure (NYHA II–IV), Ischemic Heart Disease, or Cerebrovascular Disease.
  • Severe hepatic or renal failure.
  • Treatment of perioperative pain in the setting of Coronary Artery Bypass Grafting (CABG).
  • Pregnancy in the third trimester.

Populations Requiring Caution or Restriction

  • Elderly patients must use the medicine with particular caution at the lowest effective dose.
  • Use is restricted in patients with mild to moderate renal or hepatic impairment.
  • The FDA advises avoiding use after 20 weeks of pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Uniren (Diclofenac) as described in government regulatory documents.


Interaction Classifications and Restrictions

Classification Interacting Agents
Formally Avoided (Contraindicated Combination) Other systemic Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors.
Analgesic doses of Aspirin (Acetylsalicylic acid) due to additive gastrointestinal risk.
Increased Plasma Concentration Lithium, Digoxin, Methotrexate, and Pemetrexed.
Increased Bleeding Risk (Additive PD Effect) Anticoagulants (e.g., Warfarin), Anti-platelet agents, Systemic Corticosteroids, and SSRIs/SNRIs.
Reduced Therapeutic Effect (PD Antagonism) Antihypertensive Agents (e.g., ACE inhibitors, ARBs) and Diuretics.

Mechanistic and Administration Notes

  • Metabolic Pathway Interaction: Co-administration with the strong inhibitor Voriconazole causes a documented increase in Diclofenac's plasma exposure (Cmax and AUC), primarily due to the inhibition of the CYP2C9 enzyme.
  • Renal Risk: The combination with ACE inhibitors or ARBs carries a specific risk of deterioration of renal function in high-risk patients, including the elderly and those who are volume-depleted.
  • Food Timing Constraint: For certain specific formulations, the regulatory label documents that taking the product with food may cause a reduction in effectiveness and should be avoided to ensure optimal exposure.
  • Alcohol: The use of alcohol is explicitly noted as a factor that increases the risk for serious gastrointestinal bleeding when co-administered with this medicine.

Mechanism of Action

Central Mechanisms of Action

Uniren's activity is primarily mediated by its metabolites within the central nervous system (CNS). The core mechanism involves the inhibition of the Cyclooxygenase-3 (COX-3) enzyme, an action that curtails the central synthesis of prostaglandins (specifically PGE2). These prostaglandins function as key mediators for initiating pain signal transmission and elevating the hypothalamic thermoregulatory set point. The resulting cascade involves the suppression of pain signal transmission in the spinal cord and the lowering of the elevated thermoregulatory set point in febrile states.

Beyond this central effect, the drug exerts a spasmolytic influence through the modulation of mechanisms regulating involuntary smooth muscle tone, particularly in visceral organs. This action contributes to the reduction of smooth muscle hypercontractility (spasmolysis). Uniren's profile exhibits reduced activity against peripheral inflammatory mechanisms due to minimal inhibition of peripheral COX isoforms, defining its focused central anti-mediator activity.

Dosage and Administration Information

Uniren's administration is governed by standard protocols across its multiple formulations, which include oral tablets, capsules, topical gels, and solutions for injection (IV or IM). The primary principle guiding its use is the administration of the lowest effective dosage for the shortest duration necessary to meet treatment objectives.

The dose and maximum allowable daily intake are strictly conditional on the condition being addressed. For chronic conditions, oral delayed-release tablets for osteoarthritis typically have a maximum limit of 150 mg per day, while the maximum for rheumatoid arthritis is higher, reaching 225 mg per day, both administered in divided doses. Frequency patterns often involve two to four administrations daily, depending on the specific release mechanism of the oral form.

Proper administration is essential for maintaining the intended effect. Delayed-release and extended-release tablets must be swallowed whole and should never be crushed or chewed. The powder for oral solution, which is typically reserved for acute episodes like migraine, requires mixing with only 1 to 2 ounces of plain water and must be consumed on an empty stomach.

Provisions are made for use in specific populations and handling of schedule deviations. In patients with a low body weight (under 60 kg), the maximum total daily dose should be reduced. Additionally, if a dose is missed, the approach is to skip the missed dose entirely and resume the regimen at the next scheduled time; doubling the next dose is explicitly disallowed.

Recent Clinical Evidence

Research evidence / Overview of studies for Uniren

This overview summarizes the clinical research conducted on the active ingredient in Uniren (Diclofenac), focusing on the types of studies that exist, the symptoms they have explored, and the limitations documented in the scientific and regulatory literature. This information is purely descriptive and does not offer clinical advice or instruction.


Evidence for Symptomatic Relief in Osteoarthritis (OA)

Research concerning the use of Uniren for joint pain and stiffness related to osteoarthritis (OA) has been primarily conducted through short-term Randomized Controlled Trials (RCTs). These trials were used in research exploring how symptoms change over time, and research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in adult populations.

Findings describe patterns observed in the studies where measurements tracked changes in pain and stiffness scores over the defined, short-term intervals. Studies have explored both the oral forms of Uniren and the localized topical forms, observing patterns that may relate to patient-reported discomfort. However, definitive long-term controlled efficacy trials that track sustained observation over multiple years are not as common; evidence is limited regarding the durability of these patterns over extended use.


Evidence for Inflammatory Rheumatic Conditions (RA and AS)

Research concerning chronic inflammatory conditions like Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) was studied for conditions characterized by fluctuating or episodic manifestations. These trials examined outcomes linked to inflammatory or irritative states, such as measurements of joint tenderness and swelling. Studies report how symptoms evolved in the observed populations over intermediate time intervals. Evidence contributes to the broader evidence landscape by exploring how patients reported their experience during conditions involving periods of heightened symptoms.


Study Limitations and Research Gaps

This summary highlights several areas where the evidence remains less defined. There is limited information for long-term outcomes that stem from controlled efficacy trials beyond the initial few months of use. Evidence quality varies across studies and across different formulations, and for some specific comparison points, findings were mixed. Furthermore, sample sizes were modest in some subset analyses, meaning the results apply only to the populations studied and that data for certain groups remain insufficient. Research does not determine whether an individual will respond similarly; findings describe group patterns observed in the studies, not individual predictions.

Key Studies & References

  1. Diclofenac Sodium (Oral Route) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Uniren (FAQ)


Q: Is Uniren the same type of medicine as ibuprofen?

Official information describes Uniren (Diclofenac) as a Non-Steroidal Anti-inflammatory Drug (NSAID). Ibuprofen is also classified by regulatory bodies as an NSAID. This means they belong to the same general pharmacological class, and both medicines are used to address pain and inflammation.


Q: How quickly does Uniren start to work after taking it?

Pharmacokinetic studies, which examine how the body processes the medicine, indicate that the onset of absorption for some oral formulations can be delayed, potentially between 1 and 4.5 hours. Official guidance for certain fast-acting forms notes that absorption is optimized when they are taken without food.


Q: Is it normal to feel a little dizzy after taking Uniren?

Yes, regulatory documents list dizziness as a commonly reported adverse reaction. Since the medicine affects the central nervous system, other effects like headache are also documented. The full list of reported effects is available in the official patient leaflet.


Q: Can Uniren be taken long-term?

Official guidance consistently recommends using the lowest effective dose for the shortest duration possible. Clinical data indicates that risks related to the heart and circulation, such as blood clots, may increase with higher doses and long-term treatment.


Q: What is the maximum amount of time Uniren is usually taken for?

Regulatory documents recommend the use of Uniren only for short-term treatment unless otherwise directed for a chronic condition. Official guidance advises that the need for ongoing symptomatic relief should be periodically re-evaluated to align with the recommendation for the shortest possible duration of use.


Q: Is Uniren safe to use during pregnancy?

Official information advises that the use of Uniren is generally avoided in pregnancy, particularly from 20 weeks gestation onward due to potential risks to the developing fetus. It is strictly contraindicated in the third trimester. For use prior to 20 weeks, official documents advise a careful benefit-risk assessment.


Q: Can I use Uniren if I am breastfeeding?

Regulatory documents indicate that Uniren is excreted into human milk. Because the potential effects on a nursing infant are not fully known, official guidance advises against its use while breastfeeding, and caution is advised.


Q: Does Uniren affect the stomach or cause digestive issues?

Yes, the official safety labeling for Uniren includes a Boxed Warning that highlights the risk of serious gastrointestinal adverse events. These can include inflammation, bleeding, ulceration, and perforation of the stomach or intestines.


Q: Does Uniren contain lactose or gluten?

The specific composition of Uniren, including the presence of inactive ingredients such as lactose or gluten, can vary significantly between different manufacturers and formulations. This specific information is detailed in the package leaflet or Summary of Product Characteristics (SmPC) provided with your specific version of the medicine.


Q: Can people with asthma or allergies take Uniren?

Uniren is contraindicated (must not be used) in patients who have a history of allergic-type reactions, such as asthma, hives, or swelling, after taking aspirin or other NSAIDs. Allergic reactions to Uniren may also occur in patients without prior exposure to the drug.


Q: Does Uniren cause drowsiness or make it hard to drive?

Drowsiness is listed as a possible side effect in regulatory documents. Official warnings caution patients experiencing dizziness, drowsiness, or visual disturbances against performing tasks requiring attention, such as driving or operating machinery.


Q: Can I take Uniren if I have high blood pressure?

Official warnings state that NSAIDs can sometimes cause new onset of, or worsen, pre-existing high blood pressure (hypertension). Uniren is generally not recommended for patients with uncontrolled hypertension, and blood pressure should be carefully monitored during treatment.


Q: Are there any common foods or drinks that should be avoided with Uniren?

The use of alcohol is explicitly noted in official guidance as a factor that increases the risk for serious gastrointestinal bleeding when combined with this medicine. Separately, the timing of food intake is constrained for certain specific formulations to ensure proper effectiveness.


Q: Can people with liver problems use Uniren?

Uniren is strictly contraindicated for use in patients with severe hepatic failure. The medicine's use is also restricted in patients with mild to moderate liver impairment, and potential liver enzyme elevations are monitored during treatment.


Q: Does Uniren interact with birth control pills?

Regulatory drug interaction information notes a potential for increased risk of hyperkalemia (high potassium) when Uniren is combined with oral contraceptives containing drospirenone in high-risk patients. Other birth control formulations are not consistently noted in official documents.


Q: Is Uniren addictive?

Uniren, which contains Diclofenac, is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID). Regulatory agencies do not classify it as a controlled substance with recognized potential for abuse or addiction.


Q: Is Uniren known to affect mood or cause anxiety?

Official safety data lists anxiety, depression, and confusion as adverse reactions affecting the nervous system that have been reported occasionally. These reports are part of the broader safety profile collected during clinical use.


Q: Do children need a special form of Uniren?

For children and adolescents below 14 years of age, specific formulations like oral drops or suppositories are often recommended by official guidelines. Standard adult tablets may not be appropriate for use in this younger population.


Q: What is the risk classification of Uniren for safety?

Regulatory agencies classify Uniren as an NSAID and require 'Boxed Warnings' to highlight serious safety risks, including those related to the heart and gastrointestinal system. The medicine’s classification requires that it be a prescription-only medicine for most systemic forms.


Q: Do you need a prescription to get Uniren?

Oral and injectable forms of Uniren (Diclofenac) are generally classified as prescription-only medicines (POM) by regulatory bodies. However, certain lower-strength topical formulations, such as gels, may sometimes be made available for purchase without a prescription.


Q: Is Uniren known to cause weight gain?

Regulatory documents list 'weight changes' as an adverse reaction that has been reported in clinical experience. Additionally, fluid retention (edema) is listed as a possible side effect, which can sometimes result in weight increase.


Q: Does Uniren build up in the body over time?

Pharmacokinetic data indicates the terminal half-life of Uniren is approximately 1 to 2 hours. This means the body processes and eliminates the drug relatively quickly, with little unchanged drug remaining in the system for an extended time.


Q: Does Uniren affect sleep quality?

Official safety data for Uniren lists insomnia (trouble sleeping) and dream abnormalities as adverse reactions. These effects are part of the nervous system side-effect profile occasionally reported by patients.


Q: What is the general expectation for how well Uniren works?

Regulatory guidance dictates that the medicine should only be prescribed when the benefits are considered to outweigh the potential risks. Official guidance recommends a review if symptoms persist or do not improve within the recommended duration of treatment.

How should Uniren be stored and disposed of?

The storage and disposal of Uniren (Diclofenac) must align with official regulatory requirements to ensure product quality and public safety.

Mandatory Storage Conditions

Requirement Official Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F), with excursions permitted up to 30 C or 86 F.
Protection Keep the medicine away from excessive heat, moisture, and direct light, and keep from freezing.
Container Store in the original container, which must be kept tightly closed when not in use.
Child Safety It must be stored consistently out of the sight and reach of children and pets.

Official Disposal Instructions

Disposal must adhere to pharmaceutical waste guidelines. The best option is to take any unused or expired Uniren to an authorized drug take-back program.

If a take-back program is unavailable, the product should be mixed with an undesirable substance (e.g., dirt, used coffee grounds) and sealed in a container before being placed in household trash. Do not flush the medicine down the toilet or throw it into wastewater unless specifically advised to do so by the manufacturer's labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uniren found in:

A-Z Index: